BRAIN Biotech AGHAM:BNN +0.35%66 Gross Margin % is 58.59% as of Mar. 2026, which is 6% above its 10-year median of 55.10. GuruFocus rates HAM:BNN with a GF Score™ of 66/100 and a GF Value™ of €2.56 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 1,561 Chemicals companies, BRAIN Biotech AG ranks better than 95.45% on this metric.
The historical rank and industry rank for BRAIN Biotech AG's Gross Margin % or its related term are showing as below:
HAM:BNN'
s Gross Margin % Range Over the Past 10 Years
Min: 49.5 Med: 55.1 Max: 59.4
Current: 59.4
During the past 11 years, the highestGross Margin % of BRAIN Biotech AG was 59.40%. The lowest was 49.50%. And the median was 55.10%.
HAM:BNN's Gross Margin % is ranked better than 95.45% of 1561
companies
in the Chemicals industry
Industry Median: 23.35
vs HAM:BNN: 59.40
BRAIN Biotech AG had a gross margin of 58.59% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for BRAIN Biotech AG was 0.30% per year.
BRAIN Biotech AG (HAM:BNN) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
BRAIN Biotech AG had a gross margin of 58.59% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
BRAIN Biotech AG Gross Margin % Related Terms
BRAIN Biotech AG Gross Margin % Historical Data
* Premium members only.
The historical data trend for BRAIN Biotech AG's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:BNN vs LIN, SHW, ECL: Gross Margin % Comparison
For the Specialty Chemicals subindustry, BRAIN Biotech AG's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG Gross Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Gross Margin % distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
BRAIN Biotech AG (HAM:BNN) has a Gross Margin % of 58.59% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on BRAIN Biotech AG and its competitors. This is near median its historical median of 55.10. Over the past decade, BRAIN Biotech AG's Gross Margin % has ranged from 49.50 to 59.40. According to the industry distribution chart, BRAIN Biotech AG ranks #71 out of 1561 companies in the Chemicals industry, placing it in the top 4.5%.
Is BRAIN Biotech AG's Gross Margin % too high?
BRAIN Biotech AG's current Gross Margin % of 58.59% is near median its 10-year median of 55.10. Over the past 10 years, this metric has ranged from a low of 49.50 to a high of 59.40. The Chemicals industry median Gross Margin % is 23.35. BRAIN Biotech AG's value of 58.59% is 150.9% above this industry median. Based on the distribution chart, BRAIN Biotech AG ranks #71 out of 1561 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, BRAIN Biotech AG has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's Gross Margin % compare to LIN and SHW?
According to the Chemicals industry distribution chart, BRAIN Biotech AG ranks #71 out of 1561 companies for Gross Margin %. This places BRAIN Biotech AG in the top 5% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 23.35. BRAIN Biotech AG's value of 58.59% is 150.9% above this benchmark. Historically, BRAIN Biotech AG's own Gross Margin % has ranged from 49.50 to 59.40 over the past decade. While the company's 10-year median is 55.10 vs. the industry median of 23.35, BRAIN Biotech AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Chemicals company?
The median Gross Margin % among Chemicals companies is 23.35, based on 1,561 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BRAIN Biotech AG's current Gross Margin % of 58.59% is 150.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on BRAIN Biotech AG and its competitors. For the Chemicals industry, the median Gross Margin % is 23.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BRAIN Biotech AG's current Gross Margin % is 58.59%, which is near median its own 10-year median of 55.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.56, compared to a current price of €2.83 — trading 10.5% above its estimated fair value. The current Gross Margin % is 58.59%, which is near median its 10-year median of 55.10 and 150.9% above the Chemicals industry median of 23.35. BRAIN Biotech AG's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current Gross Margin % is 58.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?
Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued.
The current stock price of €2.83 is trading 10.5% above its estimated GF Value™ of €2.56.
GuruFocus considers BRAIN Biotech AG to be Modestly Overvalued.
Key valuation signals for HAM:BNN:
Gross Margin %: 58.59% (near median its 10-year median of 55.10)
GF Value™: €2.56 vs. price of €2.83 (10.5% above fair value)
Industry Position: 150.9% above the Chemicals median (#71 of 1561)
No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
66GF Score
Get the complete analysis for HAM:BNN
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BNN has been successfully added to your 
